查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018720

脑肿瘤诊断与治疗市场：治疗方法、影像技术、肿瘤类型、肿瘤分级、患者年龄层及最终用户划分－2026年至2032年全球市场预测

Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, Tumor Type, Tumor Grade, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑肿瘤诊断和治疗市场价值将达到 19.5 亿美元，到 2026 年将成长到 21.3 亿美元，到 2032 年将达到 37.3 亿美元，复合年增长率为 9.66%。

主要市场统计数据
基准年 2025 19.5亿美元
预计年份：2026年 21.3亿美元
预测年份 2032 37.3亿美元
复合年增长率 (%) 9.66%

对目前正在重塑脑肿瘤诊断和治疗创新的临床、科学和医疗保健系统趋势进行了清晰而令人信服的概述。

脑肿瘤的诊断和治疗正处于快速发展的阶段，临床紧迫性、科学创新和医疗保健系统的变革交织在一起。分子生物学和影像学的进步重新定义了临床医生对肿瘤的分类方式，从而能够进行更精确的诊断分类，并指南个别化的治疗策略。同时，不断发展的外科技术、辅助放射治疗以及日益丰富的标靶治疗治疗方法和免疫治疗选择，无论肿瘤类型或患者年龄如何，都在重塑着脑肿瘤的治疗格局。

对重新定义脑肿瘤诊断和治疗发展的关键技术、临床和医疗保健服务变革进行详细分析，涵盖整个护理过程。

在脑肿瘤的诊断和治疗领域，多项变革正在发生，这些变革正在全面改变医疗服务的提供方式和产品的研发方式。在诊断阶段，高解析度影像和分子病理学使得超越简单的说明性分类，能够进行更精确的表型分析。这种转变有助于设计适应性临床试验和标靶治疗策略。同时，免疫肿瘤学和细胞疗法正从实验平台发展成为可操作的临床治疗方案，这需要对安全性监测、生产规模和长期追踪等方面进行新的考量。

评估近期关税主导的贸易措施将如何重塑美国脑肿瘤诊断和治疗的供应链、采购和部署趋势。

关税等政策干预措施可能对脑肿瘤诊断和治疗的生态系统产生广泛而累积的影响。影响成像设备、分子检测试剂以及用于先进外科手术和细胞疗法製造的专用耗材的进口措施，可能会增加直接采购成本，并延长关键设备的前置作业时间。这些压力可能会波及医院的资本投资计画和临床试验的后勤物流，这可能会减缓新型诊断平台的引入，并限制先进治疗方法的推广速度。

一项富有洞察力的综合細項分析，解释了治疗方法、影像创新、最终用户、肿瘤类型、恶性程度和患者年龄组如何全面决定策略重点。

从细分角度观点，我们可以更清楚地了解科学进步和商业性机会在诊断和治疗领域的集中方向。在治疗方法，化疗、免疫疗法、放射线治疗、手术和标靶治疗各自发挥不同的作用机转和临床功能。化疗包括烷化剂、抗代谢药物和含铂类药物，这些药物仍然是许多治疗方法的核心；而标靶治疗着重于抗血管新生药物、mTOR抑制剂和蛋白酪氨酸激酶抑制剂，这些药物针对分子层面的脆弱性。免疫疗法包括CAR-T细胞疗法、查核点抑制剂和疫苗平台，这些疗法推动了联合治疗的发展，并需要专门的生产和安全性监测。这些治疗方法与肿瘤的生物学特性和患者因素相互作用，从而影响治疗顺序和临床试验的设计。

一份全面的区域分析报告，描述了美洲、欧洲、中东和非洲以及亚太地区如何塑造临床引入、监管策略和商业化的路径。

地理因素是技术采纳、监管路径和商业策略的关键驱动因素。在美洲，临床试验的接受能力、创投和整合医疗网络正在推动新型诊断和治疗方法的快速普及，而强大的生物技术实用化生态系统和先进的医院基础设施也为此提供了有力支持。尤其值得一提的是，美国仍然是早期研究和产品上市的中心，区域报销制度和政策变化影响患者获得治疗的速度。

这份可操作的企业资料概述了策略联盟、平台整合和製造投资如何使脑肿瘤诊断和治疗开发领域的公司之间产生差异化。

该行业的企业发展趋势以战略联盟、平台扩张以及对生产製造和数位化能力的定向投资为特征。将诊断平台与治疗产品线结合，或与伴随诊断系统实现整合的公司，透过协调研发和商业化进程，正在获得竞争优势。在基于生物标记的患者招募和即时疗效评估需求的推动下，生物製药研发公司与诊断和影像供应商之间的合作日益活跃。

为产业领导者提供清晰且优先的建议，以加速脑肿瘤治疗的研发，降低商业性风险，并证明其临床和经济价值。

产业领导者应制定一套切实可行的优先事项，将科学预期转化为临床影响和永续的经营模式。首先，应优先投资于整合诊断技术，将分子谱分析与先进影像技术结合，以实现精准的病患筛选和入组适应性临床试验。这种方法可以降低研发风险，并提高展现显着临床效益的可能性。其次，应实现价值链多元化，并探索区域製造伙伴关係，以确保高价值投入品的持续供应，同时减轻贸易和关税的影响。

为了确保研究结果的可靠性，我们采用严谨透明的调查方法，结合文献整合、专家访谈、临床註册分析和检验程序。

本分析的调查方法整合了多种互补途径，以确保其稳健性、有效性和可操作性。该方法基于结构化的文献综述，并整合了同行评审的临床研究、指南和公开的监管文件，从而涵盖了目前的护理标准和新兴证据。除了这些二手研究外，还辅以有针对性的一手研究，包括对临床实验专家、影像专家、主要研究者和供应链管理人员的访谈，以使研究结果更具现实意义并符合实际情况。

策略结论强调，要取得脑肿瘤治疗的实质改进，需要进行综合诊断、协作开发和实证实施。

总之，脑肿瘤的诊断和治疗领域正处于一个关键的十字路口，技术进步、不断演进的临床范式和不断变化的政策环境在此交汇，既带来了机会，也带来了挑战。整合诊断和精准医疗将是未来发展的核心，但它们的实用化取决于临床专科、监管机构、保险公司和产业之间的通力合作。儘管影像学、分子谱分析和肿瘤免疫学的创新正在重新定义疾病分类和治疗路径，但供应链的韧性和策略伙伴关係对于维持和扩大医疗服务的可及性至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：脑肿瘤诊断与治疗市场（依治疗方法划分）

  • 化疗
    • 烷化剂
    • 抗代谢物
    • 含铂类药物
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
    • 疫苗疗法
  • 放射线治疗
  • 外科手术
  • 分子标靶治疗
    • 抗血管新生药物
    • mTOR抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章：影像技术在脑肿瘤诊断与治疗市场的应用

  • 电脑断层扫描
  • 磁振造影
    • 扩散张量造影
    • 功能性磁振造影
    • 光谱学
  • 分子诊断
  • 正子断层扫描
    • 胺基酸示踪剂
    • FDG
  • 超音波

第十章：依肿瘤类型分類的脑肿瘤诊断与治疗市场

  • 听神经瘤
  • 胶质瘤
  • 脑膜瘤
  • 脑下垂体瘤

第十一章：依肿瘤恶性度分類的脑肿瘤诊断与治疗市场

  • 优质
  • 低等级

第十二章：依患者年龄层分類的脑肿瘤诊断与治疗市场

  • 成人版
  • 老年人
  • 儿童

第十三章：脑肿瘤诊断与治疗市场：依最终使用者划分

  • 门诊手术中心
  • 诊断检查室
  • 医院
  • 研究机构

第十四章 脑肿瘤诊断与治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：脑肿瘤诊断与治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 脑肿瘤诊断与治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国脑肿瘤诊断与治疗市场

第十八章：中国脑肿瘤诊断与治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Mundipharma International Limited
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • VBL Therapeutics
Product Code: MRR-CA17E905E619

The Brain Tumor Diagnosis & Therapeutics Market was valued at USD 1.95 billion in 2025 and is projected to grow to USD 2.13 billion in 2026, with a CAGR of 9.66%, reaching USD 3.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.95 billion
Estimated Year [2026] USD 2.13 billion
Forecast Year [2032] USD 3.73 billion
CAGR (%) 9.66%

A clear and compelling introduction to the current clinical, scientific, and health system forces reshaping brain tumor diagnosis and therapeutic innovation

Brain tumor diagnosis and therapeutics occupy a rapidly changing intersection of clinical urgency, scientific innovation, and health system transformation. Advances in molecular biology and imaging have reframed how clinicians classify neoplasms, enabling more precise diagnostic categories that inform individualized therapeutic strategies. At the same time, evolving surgical techniques, adjunctive radiation modalities, and a growing suite of targeted and immune-based therapies are reshaping treatment pathways across tumor types and patient age cohorts.

This landscape is defined by multidimensional collaboration among neurosurgeons, neuro-oncologists, radiologists, pathologists, and translational scientists. Technology convergence-combining genomic profiling, advanced MRI sequences, and functional imaging-now supports risk-adapted care and more informed clinical decision-making. However, significant unmet needs remain, particularly for aggressive high-grade tumors and rare pediatric variants where durable responses are limited and therapeutic windows are narrow.

Consequently, stakeholders are prioritizing integrated diagnostics and therapeutic development, with emphasis on biomarker-driven trials, minimally invasive monitoring, and real-world evidence generation. This report introduces the critical themes that govern current clinical practice, innovation trajectories, and health system adoption, setting the stage for the deeper analyses that follow and framing the practical implications for developers, providers, and payers.

Detailed analysis of the major technological, clinical, and care-delivery shifts that are redefining brain tumor diagnostics and therapeutic development across the care continuum

The landscape of brain tumor diagnosis and therapeutics is undergoing several transformative shifts that collectively alter how care is delivered and how products are developed. At the diagnostic level, high-resolution imaging and molecular pathology are moving beyond descriptive classification to enable precision phenotyping; this transition supports adaptive trial designs and targeted therapeutic strategies. Concurrently, immuno-oncology and cell-based therapies are progressing from experimental platforms to viable clinical options, prompting new considerations for safety monitoring, manufacturing scale, and long-term follow-up.

Imaging innovations, including diffusion tensor imaging, functional MRI, and amino acid PET tracers, are improving lesion characterization and treatment planning, thereby enabling more conservative resections and optimized radiation targeting. Surgical advances such as intraoperative visualization and fluorescence-guided resection are enhancing extent-of-resection while preserving function, which in turn changes adjuvant therapy decision-making. On the therapeutic front, combination regimens that pair targeted agents with immune-modulatory approaches are increasingly central to clinical development, necessitating more sophisticated biomarker strategies and companion diagnostics.

Additionally, digital health, machine learning, and real-world data are gaining prominence as tools for earlier detection, prognostic modeling, and post-market surveillance. These shifts create both opportunities and complexities: developers must navigate regulatory expectations for novel modalities while health systems must adapt infrastructure to support multidisciplinary workflows and advanced diagnostics. Transitioning from siloed innovation to integrated care pathways will determine which advances translate into meaningful improvements in patient outcomes.

Assessment of how recent tariff-driven trade measures could reshape supply chains, procurement, and adoption dynamics for brain tumor diagnostics and therapeutics in the United States

Policy interventions such as tariffs can exert a broad and cumulative influence on the ecosystem that supports brain tumor diagnostics and therapeutics. Import measures affecting imaging equipment, reagents for molecular testing, and specialized consumables used in advanced surgical and cell therapy manufacturing can increase direct procurement costs and extend lead times for critical tools. These pressures ripple through hospital capital planning and clinical trial logistics, potentially delaying adoption of newer diagnostic platforms and constraining the pace at which advanced therapeutic modalities are scaled.

Manufacturers and health systems may respond by accelerating localization of supply chains and investing in domestic manufacturing capacity for high-value inputs. While onshoring can mitigate future trade-related disruptions, it also requires significant capital investment and strategic partnerships to ensure quality and regulatory compliance. For smaller developers and academic centers, increased import costs may shift prioritization toward technologies with lower capital intensity or toward licensing agreements that reduce upfront hardware requirements.

In the research domain, tariffs can alter the economics of multicenter trials that rely on uniform imaging or molecular platforms, complicating harmonization and data comparability. Clinical collaborators may need to renegotiate service contracts or adapt protocols to account for equipment heterogeneity. Ultimately, stakeholders should view tariff-related impacts as a catalyst for supply diversification, strategic procurement, and closer collaboration between industry, clinical networks, and policy makers to safeguard access to critical diagnostic and therapeutic innovations.

Insightful segmentation synthesis explaining how therapeutic modalities, imaging innovations, end users, tumor typologies, grades, and patient age groups collectively inform strategic priorities

A segmentation-aware perspective clarifies where scientific advances and commercial opportunities are concentrated across diagnostic and therapeutic axes. Within therapeutic modality, chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy each contribute distinct mechanisms and clinical roles; chemotherapy includes alkylating agents, antimetabolites, and platinum compounds that remain core to many regimens, while targeted therapies emphasize antiangiogenic agents, mTOR inhibitors, and tyrosine kinase inhibitors focused on molecular vulnerabilities. Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccine platforms that are driving combination strategies and necessitating specialized manufacturing and safety monitoring. These modalities interact with tumor biology and patient factors to shape treatment sequencing and trial design.

On the diagnostic imaging side, the market is organized across computed tomography, magnetic resonance imaging, molecular diagnostics, positron emission tomography, and ultrasound. Magnetic resonance imaging further segments into diffusion tensor imaging, functional MRI, and spectroscopy that enhance structural and functional assessment, whereas positron emission tomography leverages amino acid tracers and FDG for improved metabolic evaluation. End users are defined across ambulatory surgical centers, diagnostic laboratories, hospitals, and research institutes, each exhibiting different capital intensity, workflow needs, and decision-making authority for technology adoption.

Tumor-type segmentation spans acoustic neuroma, glioma, meningioma, and pituitary tumor with divergent clinical courses and regulatory pathways, and tumor-grade classification into high grade and low grade remains pivotal for prognosis and treatment aggressiveness. Patient age cohorts-adult, geriatric, and pediatric-introduce distinct biological considerations, dosing imperatives, and regulatory protections, especially in pediatric populations where long-term neurocognitive outcomes are critical. Integrating these segmentation lenses reveals that investment and clinical emphasis are concentrated where molecularly targetable biology, unmet clinical need, and feasible delivery pathways converge.

Comprehensive regional analysis describing how Americas, Europe Middle East & Africa, and Asia-Pacific each shape clinical adoption, regulatory strategy, and commercialization pathways

Geographic dynamics are a key determinant of technology adoption, regulatory pathways, and commercial strategy. In the Americas, clinical trial capacity, venture investment, and integrated care networks drive rapid uptake of novel diagnostics and therapeutics, complemented by a strong ecosystem for biotech translation and advanced hospital infrastructure. The United States in particular remains a focal point for early-phase studies and commercial launches, with regional reimbursement and policy changes influencing speed of access.

The Europe, Middle East & Africa region exhibits heterogeneous healthcare systems and regulatory environments, with pockets of excellence in advanced neuro-oncology centers and national research networks. European regulatory frameworks emphasize rigorous evidence and cost-effectiveness, while several Gulf and North African markets are investing in tertiary care capacity, creating selective demand for high-value interventions. These variations require tailored market access strategies and localized evidence generation.

Asia-Pacific is characterized by rapid adoption curves in urban centers, growing domestic manufacturing capabilities, and demographic trends that expand demand for neuro-oncology services. Cost sensitivity and diverse reimbursement landscapes in the region necessitate flexible pricing and partnership models, while several Asian countries are emerging as key sites for late-stage clinical trials due to patient volume and operational efficiencies. Cross-regional collaboration and technology transfer are increasingly important to ensure consistent standards of care and to scale innovations globally.

Actionable corporate intelligence outlining how strategic partnerships, platform integration, and manufacturing investments differentiate companies in brain tumor diagnostics and therapeutic development

Company behavior in this sector is characterized by strategic partnerships, platform extension, and targeted investments in manufacturing and digital capabilities. Firms that combine diagnostic platforms with therapeutic pipelines or that secure companion diagnostic linkages gain competitive advantage by aligning development and commercialization timelines. Collaboration between biopharma developers and diagnostics or imaging vendors is intensifying, driven by the need for biomarker-driven enrollment and real-time response assessment.

Key corporate strategies include forming consortiums to de-risk early clinical development, outsourcing specialized manufacturing for cell and gene therapies, and investing in cloud-based platforms for imaging analysis and longitudinal outcome monitoring. Mergers and acquisitions continue to be a lever for rapid capability acquisition, particularly for companies seeking to integrate molecular testing, imaging analytics, and clinical decision support into a coherent offering. Smaller innovators are frequently acquired or enter co-development agreements to scale manufacturing and regulatory expertise, while larger organizations focus on platform consolidation and global market access.

Across the competitive landscape, agility in forging payer relationships and demonstrating health economic value is becoming as important as scientific differentiation. Companies that proactively address real-world implementation challenges, simplify clinical workflows, and provide training and support to health systems are more likely to achieve durable adoption and sustained commercial performance.

Clear and prioritized recommendations for industry leaders to accelerate development, mitigate commercial risks, and demonstrate clinical and economic value in brain tumor care

Industry leaders should adopt a set of pragmatic, actionable priorities to convert scientific promise into clinical impact and sustainable business models. First, prioritize investment in integrated diagnostics that link molecular profiling with advanced imaging to enable precise patient selection and adaptive trial enrollment. This approach reduces development risk and enhances the likelihood of demonstrating meaningful clinical benefit. Second, diversify supply chains and consider regional manufacturing partnerships to mitigate trade and tariff exposure while ensuring continuity for high-value inputs.

Third, pursue combination strategies deliberately by aligning regulatory and safety pathways early in development and by establishing standardized biomarker strategies to streamline approval and reimbursement. Fourth, engage payers and health technology assessment bodies early to define evidence requirements and case definitions that support value-based contracting. Fifth, invest in real-world evidence and data infrastructure that captures longitudinal outcomes, quality-of-life metrics, and health economic endpoints to support uptake and formulary inclusion.

Finally, strengthen cross-sector collaborations with academic centers, patient advocacy organizations, and surgical and radiology networks to accelerate clinical adoption, improve trial recruitment, and ensure that innovations address practical care delivery constraints. These steps will help organizations reduce time to market, enhance value demonstration, and ultimately improve patient outcomes in a complex therapeutic area.

Rigorous and transparent research methodology combining literature synthesis, expert interviews, clinical registry analysis, and validation steps to ensure trustworthy insights

The research methodology underpinning this analysis integrates multiple complementary approaches to ensure robustness, validity, and practical relevance. The foundation comprises structured literature review and synthesis of peer-reviewed clinical studies, guidelines, and publicly available regulatory documents to capture the current standard of care and emergent evidence. This secondary research is augmented with targeted primary research, including interviews with clinical experts, imaging specialists, trial investigators, and supply chain managers to contextualize findings and confirm operational realities.

Data triangulation is used to reconcile differing inputs and to validate thematic conclusions. Clinical trial registries and recent conference proceedings are reviewed to map active development programs and to identify nascent therapeutic and diagnostic trends. Where appropriate, technical specifications and product labeling are analyzed to understand capabilities, limitations, and integration requirements. The methodology also includes scenario analysis to test how variables such as regulatory shifts, reimbursement changes, or supply-chain disruptions might affect adoption curves.

Limitations are acknowledged, including variability in regional practice patterns and the evolving nature of early-phase clinical evidence. To address these constraints, findings are presented with clarity about evidence level and are supplemented by expert judgment. Ethical standards and data integrity practices guide all primary engagements, and confidential input from experts is synthesized to preserve anonymity while preserving actionable insight.

Strategic conclusion emphasizing the need for integrated diagnostics, coordinated development, and evidence-driven adoption to realize meaningful improvements in brain tumor care

In conclusion, the field of brain tumor diagnosis and therapeutics stands at a pivotal juncture where converging technological advances, evolving clinical paradigms, and shifting policy environments create both opportunity and complexity. Integrated diagnostics and precision-directed therapeutics are central to future progress, but their successful translation will depend on coordinated efforts across clinical specialties, regulators, payers, and industry. Innovations in imaging, molecular profiling, and immuno-oncology are redefining disease classification and treatment pathways, while supply-chain resilience and strategic partnerships are essential to sustain access and scale.

Stakeholders that invest in linkage between diagnostics and therapeutics, proactively manage commercial and regulatory risk, and prioritize real-world evidence generation will be best positioned to realize durable clinical and economic outcomes. The imperative is to move beyond isolated breakthroughs toward systems-level integration that improves patient selection, optimizes therapeutic sequencing, and preserves quality of life. Doing so will require disciplined execution, clear demonstration of value, and a patient-centered focus that aligns scientific ambition with deliverable clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Therapeutics Market, by Therapeutic Modality

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Platinum Compounds
  • 8.2. Immunotherapy
    • 8.2.1. CAR T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccine Therapy
  • 8.3. Radiation Therapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Antiangiogenic Agents
    • 8.5.2. MTOR Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Brain Tumor Diagnosis & Therapeutics Market, by Imaging Technology

  • 9.1. Computed Tomography
  • 9.2. Magnetic Resonance Imaging
    • 9.2.1. Diffusion Tensor Imaging
    • 9.2.2. Functional MRI
    • 9.2.3. Spectroscopy
  • 9.3. Molecular Diagnostics
  • 9.4. Positron Emission Tomography
    • 9.4.1. Amino Acid Tracers
    • 9.4.2. FDG
  • 9.5. Ultrasound

10. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Type

  • 10.1. Acoustic Neuroma
  • 10.2. Glioma
  • 10.3. Meningioma
  • 10.4. Pituitary Tumor

11. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Grade

  • 11.1. High Grade
  • 11.2. Low Grade

12. Brain Tumor Diagnosis & Therapeutics Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Brain Tumor Diagnosis & Therapeutics Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Brain Tumor Diagnosis & Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Brain Tumor Diagnosis & Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Tumor Diagnosis & Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Brain Tumor Diagnosis & Therapeutics Market

18. China Brain Tumor Diagnosis & Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Agios Pharmaceuticals, Inc.
  • 19.7. Amgen Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bayer AG
  • 19.10. Bristol Myers Squibb Company
  • 19.11. Eli Lilly and Company
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. GlaxoSmithKline plc
  • 19.14. Ipsen Pharma
  • 19.15. Johnson & Johnson
  • 19.16. Karyopharm Therapeutics Inc.
  • 19.17. Merck & Co., Inc.
  • 19.18. Mundipharma International Limited
  • 19.19. Novartis AG
  • 19.20. Novocure GmbH
  • 19.21. Pfizer Inc.
  • 19.22. Sanofi S.A.
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. VBL Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 242. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 277. G7 BRAIN TUMOR DIAGNO